Graft vs Host Disease (GVHD) – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030

 

Indication name: Graft vs Host Disease (GVHD)

Graft vs Host Disease (GVHD) – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030 (Markets covered: US, Germany, France, Spain, United Kingdom, Italy, Japan & China)

Graft vs Host Disease (GVHD) is a pattern of transplant rejection in which donor immune cells mount an immune response against host tissues. GVHD occurs when the donor’s T cells (the graft) view the patient’s healthy cells (the host) as foreign, and attack and damage them. Graft-versus-host disease can be mild, moderate or severe. In some cases, it can be life-threatening.

CRPS can be classified in 2 types, Acute GVHD- develops within the first 100 days after transplantation. Chronic GVHD- It is one of the leading causes of medical problems and death after an allogeneic stem cell transplantation

According to Thelansis estimates, In the US, the incidence of chronic GVHD ranges from 6% to 80%. GVHD is considered one of the main causes of morbidity and mortality after HCT; more than 10% of patients will die from this complication.

Competitive landscape of Graft vs Host Disease (GVHD) includes country specific approved as well as pipeline therapies. Any asset/ product specific designation or review and Accelerated Approval are being tracked and supplemented with analyst commentary.

KOLs insights of Graft vs Host Disease (GVHD) across 8 MM market from center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm and Unmet needs.

Graft vs Host Disease (GVHD) Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard) which Data Inputs with sourcing, Market Event and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden and pricing scenario, Summary and Insights.

Read more: Graft vs Host Disease (GVHD) – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030  

S. No     Asset     Company           Stage

1            ibrutinib             Pharmacyclics LLC.          Phase 3

2            ECP Methoxsalen            Mallinckrodt      Phase 1

3            ECP Methoxsalen            Parexel Phase 1

4            ibrutinib             Janssen Research & Development, LLC    Phase 3

5            Itacitinib             Incyte Corporation         Phase 3

6            Pro-ocular™ Topical Gel 1%         Glia, LLC              Phase 3

7            Efavaleukin Alfa Amgen  Phase 2

8            Alpha-1 antitrypsin (AAT)            CSL Behring        Phase 3

9            Pro-ocular™ topical gel  ORA, Inc.            Phase 2

10          Ruxolitinib         Novartis Pharmaceuticals            Phase 2

11          axatilimab          Syndax Pharmaceuticals Phase 2

12          [18F]F-Ara-G      CellSight Technologies, Inc.         Phase 1

13          ASC930 ASC Therapeutics            Phase 2

14          SCM-CGH           SCM Lifescience Co., LTD.            Phase 2

15          Defibrotide        Jazz Pharmaceuticals     Phase 2

16          R348 Ophthalmic Solution, 0.2%              Rigel Pharmaceuticals              Phase 2

17          MC0518              medac GmbH    Phase 3

18          Umbilical cord derived mesenchymal stem cell   Cytopeutics Sdn. Bhd.      Phase 2

19          Neihulizumab (AbGn-168H)        AltruBio Inc.       Phase 1

20          Prochymal          Mesoblast, Inc. Phase 3

21          KD025   Kadmon Corporation, LLC            Phase 2

22          Ibrutinib             Janssen Pharmaceutical K.K.       Phase 3

23          Mesenchymoangioblast-derived mesenchymal stem cells              Cynata Therapeutics Limited       Phase 1

24          natalizumab      Biogen  Phase 2

25          EQ001   Equillium            Phase 2

26          EQ001   Biocon Limited  Phase 2

27          T-Guard              Xenikos Phase 2

28          Recombinant Human Interleukin-22 IgG2-Fc (F-652)        Generon (Shanghai) Corporation Ltd.        Phase 2

29          ApoGraft            Cellect Biotechnology    Phase 1

30          PRO 140              CytoDyn, Inc.     Phase 2

31          UTTR1147A        Genentech, Inc. Phase 1

32          Brimonidine Tartrate     Ocugen Phase 3

33          Vedolizumab     Millennium Pharmaceuticals, Inc.            Phase 3

34          Belimumab        GlaxoSmithKline              Phase 1

35          Glasdegib           Pfizer    Phase 2

36          Acalabrutinib    AstraZeneca      Phase 2

37          MaaT013            MaaT Pharma    Phase 3

38          Pacritinib            CTI BioPharma  Phase 2

39          CD24Fc OncoImmune, Inc.          Phase 3

40          US-ATG-F            Neovii Biotech   Phase 3

41          CBD       Kalytera Therapeutics Israel, Ltd.             Phase 2

42          Inolimomab (Leukotac) ElsaLys Biotech  Phase 3

43          BPX-501 and Rimiducid Bellicum Pharmaceuticals           Phase 1

44          ProTmune          Fate Therapeutics           Phase 2

45          FLUDARABINE   Regimmune Corporation             Phase 1

46          ATIR101              Kiadis Pharma   Phase 2

47          EAGD T-cell infusion (Phase I)     In8bio Inc.          Phase 1

48          IFN-γ (interferon gamma-1b) injection    Horizon Pharma USA, Inc.              Phase 1

49          Fludarabine       Sanofi   Phase 3

50          Fludarabine       Celgene Corporation      Phase 2"